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not routinely recommended.4-6 The results of ran‑
domized controlled trials of ARAS revasculariza‑
tion have been largely neutral in terms of blood 
pressure (BP) and / or renal function (RF) im‑
provement, as compared with best medical ther‑
apy (BMT).4,7,8 Clinical series focused on BP and 
RF outcomes in selected patients have reported 
INTROduCTION Atherosclerotic renal artery ste‑
nosis (ARAS) is a relatively frequent disease, es‑
pecially in older patients or those with either 
coronary or extracoronary athero ‑occlusive dis‑
ease.1-3 Some patients benefit from ARAS revas‑
cularization, but the intervention (stent ‑assisted 
percutaneous transluminal angioplasty [PTA]) is 
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INTROduCTION There are no systematic tools to predict blood pressure (BP) or renal function (RF) 
improvement after stent ‑assisted percutaneous transluminal angioplasty (PTA) for atherosclerotic renal 
artery stenosis (ARAS).
ObjECTIvEs This study aimed to develop simple, clinically applicable scores based on preprocedural clini‑
cal and renal ultrasonography parameters in order to predict BP and RF improvement following ARAS ‑PTA.
PATIENTs ANd mEThOds A total of 202 patients who underwent ARAS ‑PTA were categorized as 
RF responders (eGFR increase ≥11 ml/min/1.73 m2) or BP responders (systolic and diastolic BP de‑
crease ≥20 mm Hg and ≥5 mm Hg, respectively) at 12 months following ARAS ‑PTA. The variables 
associated with the RF or BP response in univariable analysis were included in a multivariable logistic 
regression model. Point ‑based response scales were developed proportionally to odds ratios in each of 
the 2 models to embrace the maximum score of 10.
REsuLTs The BP response to ARAS ‑PTA was 93.3% in the high ‑probability category (6–10 points), 
66.7% in the medium ‑probability category (3–5 points), and 25.3% in the low ‑probability category (0–2 
points), with the preprocedural variables of systolic BP ≥145 mm Hg (3 points), diastolic BP ≥83 mm Hg 
(4 points), PTA of a single functioning kidney (2 points), and bilateral PTA (1 point). The RF response 
was 77.3% in the high ‑probability category (8–10 points), 33% in the medium ‑probability category (4–7 
points), and 10.9% in the low ‑probability category (0–3 points) for serum creatinine levels >122 μmol/l 
and eGFR >30 ml/min/1.73 m2 (3 points), index kidney length >98 mm (3 points), renal artery end‑
‑diastolic velocity >1.1 m/s (2 points), and arterial resistive index <0.74 (2 points).
CONCLusIONs Models of favorable BP and RF response may improve patient selection for ARAS ‑PTA. 
Further insights are expected from prospective validation.
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(the seventh report).17 Hypertension was defined 
as systolic and / or diastolic BP ≥140 mm Hg 
and ≥90 mm Hg, respectively. Blood pressure 
evaluation was based on an average of 2 BP mea‑
surements performed in a patient in a sitting 
position, within 5 ‑minute intervals during sep‑
arate outpatient office visits that followed opti‑
mization of pharmacotherapy.
Fasting blood samples, including serum creati‑
nine, were taken upon admission. Renal function 
assessment including serum creatinine levels and 
eGFR was performed prior to PTA. The value of 
eGFR was estimated from the Modification of Diet 
in Renal Disease (MDRD) formula, according to 
the following equation: MDRD = 175 × creatinine 
[mg/dl]−1.154 × age [years]−0.203 × 0.742 [if female].
Assessment of renal flow parameters and the kidneys 
on doppler ultrasonography Doppler ultrasonog‑
raphy was performed in a supine and / or left or 
right lateral position, depending on which renal 
artery was assessed. The examination was per‑
formed by 2 operators, using a high ‑resolution 
ultrasonograph (TOSHIBA APLIO [Canon Med‑
ical Systems GmbH,  Neuss, Germany] with 
a 3.5–5 ‑MHz probe). The assessment included 
the following parameters: systolic velocity in 
the aorta, peak systolic and end ‑diastolic veloc‑
ity (EDV) in the index renal artery, the renal‑
‑aortic ratio, the resistive index (RI) in the renal 
artery, the intrarenal RI, acceleration time, and 
the pole ‑to ‑pole kidney length of the index and 
contralateral kidneys.
Renal artery stenting The PTA procedure was de‑
scribed in detail elsewhere.16 In brief, PTA was 
performed according to the standard protocol. 
All patients received dual antiplatelet therapy 
before the procedure, which was continued for 3 
months after PTA, and then, single antiplatelet 
therapy was continued indefinitely. The choice of 
stent type and route of vascular access was left 
at the operator’s discretion. A distal embolic pro‑
tection device was used during a single procedure.
Follow -up examinations Follow ‑up including 
the evaluation of clinical symptoms, BP, and RF 
was conducted before discharge and at 6 and 12 
months following PTA. The protocol for BP mea‑
surement and RF evaluation was the same as that 
used before PTA.
The study patients were categorized as re‑
sponders or nonresponders in 2 categories: re‑
sponders versus nonresponders in terms of BP 
or eGFR. Cutoff values for responders were de‑
fined as a systolic and diastolic BP reduction of 
at least 20 mm Hg and 5 mm Hg or greater, re‑
spectively, or an eGFR increase greater than 
11 ml/min/1.73 m2 and adopted from the previ‑
ously published study on the reduction of cardio‑
vascular death, myocardial infarction, or stroke 
risk following PTA for ARAS.16 Nonresponders 
were defined as patients showing no improve‑
ment in systolic or diastolic BP or eGFR.
improved BP control in up to 65% of patients and 
RF improvement in approximately 30% to 40% 
of patients.4,9,10
Identifying responders to the treatment—pri‑
or to ARAS ‑PTA—poses the major problem.11 
There are no clinical scores or decision making 
trees that would guide clinicians on patient se‑
lection either for BMT or PTA plus BMT. In con‑
sequence, guidelines addressing patient selection 
for ARAS ‑PTA are vague and leave clinicians with‑
out clear guidance.12
The issue is of clinical importance, as improve‑
ment in BP and RF translates into reduced risk of 
cardiovascular events.4,6,13-15 We noted that an in‑
crease in the estimated glomerular filtration rate 
(eGFR) by at least 11 ml/min/1.73 m2 as well as 
systolic and diastolic BP decrease by 20 mm Hg 
and 5 mm Hg or greater, respectively, following 
PTA for ARAS, are related to cardiovascular death 
or stroke risk reduction over 5 years.16
Therefore, the aim of the present study was to 
develop clinically applicable scores incorporating 
routine preprocedural parameters to predict BP 
and RF response following PTA for ARAS.
PATIENTs ANd mEThOds study population From 
January 2003 to December 2018, 202 patients 
with ARAS (60% to 99% lumen diameter steno‑
sis on quantitative angiography) underwent PTA 
for ARAS provided that they had presented with 
accelerated or refractory hypertension on at least 
3 antihypertensive drugs and / or RF impairment. 
Exclusion criteria were nonatherosclerotic renal 
artery stenosis, nondiagnostic renal ultrasonog‑
raphy, and lack of informed consent to partici‑
pate in the study.
All patients provided informed consent before 
enrollment in accordance with the requirements 
of the local ethics committee (KBET/392/B/2003). 
The study was performed in line with the princi‑
ples of the Declaration of Helsinki.
blood pressure and renal function evaluation Data 
were collected on patient admission to the depart‑
ment, prior to any intervention, immediately af‑
ter signed informed consent was obtained from 
the patients.
Blood pressure was measured according to 
the guidelines published by the Joint Nation‑
al Committee on Prevention, Detection, Eval‑
uation, and Treatment of High Blood Pressure 
whAT’s NEw?
Current guidelines on atherosclerotic renal artery stenosis (ARAS) revascular‑
ization (stent ‑assisted percutaneous transluminal angioplasty [PTA]) offer little 
aid in clinical decision making. No baseline clinical, parameter ‑based scores for 
the assessment of the response to treatment have been established yet. Based 
on a detailed evaluation of a large ARAS ‑PTA patient cohort, we developed 
clinical scores to predict blood pressure and renal function response following 
ARAS revascularization. These simple scores may serve as useful tools to guide 
clinicians in patient selection for ARAS ‑PTA.
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Following PTA, mean (SD) systolic and diastolic 
BP compared with the baseline values was 134.3 
(17.8) mm Hg versus 150 (25) mm Hg (P <0.001) 
and 75.5 (10.8)  mm  Hg vs 83 (13)  mm  Hg 
(P <0.001), respectively. A systolic BP decrease 
of 20 mm Hg or greater and a diastolic BP de‑
crease of 5 mm Hg or greater were observed in 
122 patients (60.4%).
Furthermore, a significant increase in the 
mean (SD) eGFR compared with the baseline val‑
ues, ie, 56 (23.4) mm Hg versus 52.3 (21.6) mm Hg 
(P = 0.003), was observed at 12 ‑month follow ‑up. 
An eGFR increase greater than 11 ml/min/1.73 m2 
was noted in 56 patients (27.7%).
Univariable logistic regression analysis indi‑
cated several parameters that may have impact 
on the probability of BP and RF response (TAbLE 1).
The model of favorable blood pressure response 
A positive BP response, defined as systolic and 
diastolic BP decrease of at least 20 mm Hg and 
5 mm Hg respectively, was associated with the fol‑
lowing preprocedural parameters in univari‑
able analysis: systolic BP ≥145 mm Hg (area un‑
der the curve [AUC], 0.792; P <0.001), diastolic 
BP ≥83 mm Hg (AUC, 0.837; P <0.001), PTA of 
a single functioning kidney (OR, 1.25; P = 0.009), 
and PTA for bilateral ARAS (OR, 1.13; P = 0.05), 
whereas a negative response was related to con‑
tralateral kidney length ≥122 mm (AUC, 0.398; 
P = 0.007).
Multivariable analysis identified 4 inde‑
pendent predictors of BP response: 1) base‑
line systolic BP ≥145 mm Hg (OR, 5.42; 95%  CI, 
2.64–11.1; P  <0.001); 2) baseline diastolic 
BP ≥83 mm Hg (OR, 6.63; 95% CI, 3.07–14.3; 
P <0.001); 3) PTA of a single functioning kidney 
(OR, 3.09; 95% CI, 0.92–10.4; P = 0.066); and 
4) PTA for bilateral ARAS (OR, 2.56; 95% CI, 
1.2–5.49; P = 0.015).
The BP response score comprised 4 preproce‑
dural variables (points): systolic BP ≥145 mm Hg 
(3 points) and diastolic BP ≥83 mm Hg (4 points), 
PTA of a single functioning kidney (2 points), and 
bilateral PTA (1 point).
The prevalence of responders was 93.3% (70 of 
75 patients) in the high ‑probability category (≥6 
points), 66.7% (32 of 48 patients) in the medium‑
‑probability category (3–5 points), and 25.3% 
(20 of 79 patients) in the low ‑probability cate‑
gory (0–2 points).
The model of favorable renal function response A pos‑
itive RF response, defined as an eGFR increase 
of at  least 11  ml/min/1.73  m2, was associat‑
ed with the  following preprocedural parame‑
ters in univariable analysis: serum creatinine lev‑
el ≥122 µmol/l (AUC, 0.601; P = 0.016), index 
kidney length >98 mm (AUC, 0.609; P = 0.007), 
EDV >1.1 m/s in the index renal artery (AUC, 0.61; 
P = 0.009), and index artery RI <0.74 (AUC, 0.678; 
P <0.001), whereas a negative response was asso‑
ciated with eGFR <30 ml/min/1.73 m2 (AUC, 0.43; 
P = 0.09).
statistical analysis Continuous variables were 
presented as mean (SD), and categorical vari‑
ables were expressed as numbers and percentag‑
es. Differences between mean values were veri‑
fied using the t test and the analysis of variance, 
and categorical variables were compared using 
the χ2 test for independence, as appropriate. 
The normal distribution of the analyzed vari‑
ables was determined by the Shapiro–Wilk test.
Construction of models for the prediction of blood pres-
sure and renal function improvement after percutane-
ous transluminal angioplasty Step 1: BP and RF 
outcomes were analyzed as a dichotomous vari‑
able (responder versus nonresponder).
The potential independent prognostic markers 
of BP and RF response during the follow ‑up pe‑
riod were established based on clinical, Doppler 
ultrasonography, and angiographic variables by 
univariable analysis (TAbLE 1).
Step 2: receiver operating characteristic anal‑
ysis was performed to determine optimal cutoff 
values (the common point of the most distant 
y = x line with the receiver operating characteris‑
tic curve) for continuous variables established as 
potentially associated with RF and BP response 
based on univariable analysis.
Step 3: after identifying preprocedural param‑
eters and their cutoffs associated with favorable 
BP and RF outcomes following PTA, multivariable 
logistic backward regression analysis was used to 
calculate adjusted odds ratios (ORs) and 95% CIs 
for improvement in each of the 2 outcomes (BP 
or RF responder).
Points were assigned according to the regres‑
sion coefficients of each independent variable in 
each of the 2 models to embrace the maximum 
score of 10 and proportionally to the OR values.
Step 4: score interpretation. The score was re‑
garded as indicative of a low probability of favor‑
able BP or RF response, if less than 30% of pa‑
tients with this score presented with BP or RF 
improvement.
The score was considered as showing a medi‑
um probability of favorable BP or RF response, 
if 31% to 70% of patients with this score exhib‑
ited BP or RF improvement.
The score was regarded as indicative of a high 
probability of favorable BP or RF response, if more 
than 70% of patients with this score showed BP 
or RF improvement. These rules determined point 
limits in total scores, so they can be used for pre‑
diction purposes.
Statistical analyses were performed using 
the Statistica 13.0 software (StatSoft Polska, 
Kraków, Poland). A P value less than 0.05 was 
considered significant, unless otherwise stated.
REsuLTs The detailed characteristics of the 
study patients and index lesions are shown in 
TAbLE 2. Percutaneous transluminal angioplasty 
was performed for unilateral RAS in 137 patients 
(67.8%), bilateral RAS in 35 (17.3%), and RAS of 
a single functioning kidney in 30 (14.9%).
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level >122 µmol/l and eGFR >30 ml/min/1.73 m2 
(3 points), index kidney length >98 mm (3 points), 
EDV in ARAS >1.1 m/s (2 points), and renal ar‑
tery RI <0.74 (2 points).
The  prevalence of responders was 77.3% 
(17 of 22 patients) in the high ‑probability cat‑
egory (≥8 points), 33% (29 of 88 patients) in 
the medium ‑probability category (4–7 points), 
and 10.9% (10 of 92 patients) in the  low‑
‑probability category (0–3 points).
dIsCussION The  key finding of this study 
is the development of simple preprocedural, 
In multivariable logistic regression analysis, 
RF improvement was associated with the follow‑
ing findings: 1) preprocedural serum creatinine 
level >122 µmol/l and eGFR >30 ml/min/1.73 m2 
(OR, 3.71; 95% CI, 1.88–7.32; P <0.001); 2) in‑
dex kidney length >98 mm (OR, 3.21; 95% CI, 
1.63–6.32; P = 0.001); 3) EDV  >1.1  m/s in 
the index renal artery (OR, 2.72; 95% CI, 1.35–
5.48; P = 0.005); and 4) preprocedural index 
artery RI <0.74 (OR, 2.33; 95% CI, 1.19–4.56; 
P = 0.013).
The RF response score comprised the following 
variables (points): preprocedural serum creatinine 
TAbLE 1 Univariable logistic regression analysis for blood pressure and renal function at 12 months following angioplasty for renal artery stenosis in 
treatment responders and nonresponders
Variable SBP and DBP decrease of 20 mm Hg and 
5 mm Hg or greater, respectively
eGFR increase of 11 ml/min/1.73 m2 
or greater
OR (95% CI) P value OR (95% CI) P value
Age (per 1 year) 0.92 (0.81–1.05) 0.21 1.14 (0.99–1.31) 0.07
Female sex 1.05 (0.92–1.19) 0.48 1.07 (0.93–1.23) 0.32
More than 3 blood ‑lowering drugs 1.08 (0.95–1.23) 0.89 0.7 (0.56–0.87) 0.001
Diabetes 1.02 (0.89–1.18) 0.75 1.07 (0.94–1.22) 0.31
Hyperlipidemia 1.06 (0.92–1.22) 0.41 0.97 (0.86–1.11) 0.7
Smoking status 1.01 (0.88–1.16) 0.91 1.12 (0.98–1.29) 0.11
BMI (per 1 kg/m2) 0.88 (0.75–1.03) 0.1 1.04 (0.88–1.23) 0.67
Previous MI 1.12 (0.99–1.27) 0.07 1.18 (1.03–1.36) 0.017
Previous stroke 1 (0.86–1.15) 0.94 1.04 (0.91–1.2) 0.56
Prior flash pulmonary edema 0.94 (0.82–1.08) 0.37 1.02 (0.88–1.17) 0.82
Prior hypertensive crisis 1.06 (0.92–1.22) 0.43 1.03 (0.9–1.19) 0.66
LVEF <45% 1.03 (0.9–1.17) 0.68 0.99 (0.86–1.13) 0.87
Internal carotid artery stenosis 1.14 (1.01–1.3) 0.04 1 (0.87–1.16) 0.96
CAD 1.08 (0.95–1.23) 0.21 0.96 (0.84–1.11) 0.59
Lower extremity occlusive disease 1 (0.87–1.15) 0.66 1 (0.87–1.15) 0.98
Baseline SBP ≥145 mm Hg 1.53 (1.36–1.71) <0.001 0.96 (0.85–1.1) 0.59
Baseline DBP ≥83 mm Hg 1.7 (1.52–1.89) <0.001 1.04 (0.92–1.19) 0.54
Baseline creatinine >122 µmol/l 1.1 (0.97–1.25) 0.13 1.17 (1.03–1.32) 0.019
Baseline eGFR <30 ml/min/1.73 m2 1.18 (0.94–1.34) 0.48 0.51 (0.32–0.83) 0.007
Angiographic and procedural data
Bilateral vs unilateral PTA 1.13 (1–1.28) 0.05 1.1 (0.95–1.26) 0.19
PTA of a single functioning kidney 1.25 (1.09–1.44) 0.009 1.06 (0.93–1.22) 0.39
Degree of RAS (per 1%) 1.08 (0.95–1.23) 0.24 0.96 (0.84–1.09) 0.52
Stent diameter (per 1 mm) 1.17 (1.03–1.33) 0.015 1.23 (1.08–1.4) 0.002
Stent length (per 1 mm) 0.79 (0.61–1.1) 0.58 1.01 (0.89–1.15) 0.84
Predilation 0.9 (0.79–1.02) 0.1 0.94 (0.83–1.07) 0.38
Doppler ultrasonography parameters
Peak systolic velocity in index RAS (per 0.1 m/s) 0.94 (0.83–1.07) 0.35 0.82 (0.61–1.1) 0.19
End ‑diastolic velocity in index RAS >1.1 m/s 0.98 (0.85–1.11) 0.72 1.23 (1.08–1.40) 0.002
Renal ‑aortic ratio in index RAS >5.1 1 (0.88–1.13) 0.95 1.09 (0.96–1.24) 0.2
Resistive index in index RAS <0.74 0.94 (0.83–1.07) 0.37 1.27 (1.12–1.44) <0.001
Intrarenal resistive index in index RAS <0.7 0.95 (0.84–1.09) 0.47 1.24 (1.09–1.41) 0.001
Index kidney length >98 mm 1.02 (0.89–1.16) 0.82 1.23 (1.08–1.41) 0.002
Contralateral kidney length >122 mm 0.84 (0.74–0.95) 0.007 1.05 (0.91–1.2) 0.23
Abbreviations: BMI, body mass index; CAD, coronary artery disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; 
LVEF, left ventricular ejection fraction; MI, myocardial infarction; OR, odds ratio; PTA, percutaneous transluminal angioplasty; RAS, renal artery 
stenosis; SBP, systolic blood pressure
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We propose 2 simple prediction scores, sep‑
arately for BP and RF improvement (TAbLE 3), 
which are based on preprocedural systolic and 
diastolic BP values that remain increased regard‑
less of maximized blood pressure–lowering med‑
ication, preprocedural serum creatinine levels 
and eGFR, as well as ARAS parameters on renal 
ultrasonography.
There has been an increasing understanding 
of the fact that ARAS ‑PTA is an option neither 
for (nearly) “all” patients with ARAS (like in the 
inclusion criteria of randomized studies) nor 
for “none” of these patients (like, seemingly, in 
the outcomes of randomized studies), but the field 
lacks clinically applicable tools for the prediction 
of a favorable clinical response.15,18-20
The scores developed in this study are clinical‑
ly relevant, as they are based on simple param‑
eters (TAbLE 3), which are routinely examined in 
everyday clinical practice for the evaluation of 
patients with ARAS, and our thresholds for re‑
sponses labeled as favorable have been shown to 
be associated with a reduced risk of cardiovascular 
events and cardiovascular death.16,21,22 As previ‑
ously reported, lowering systolic BP by 20 mm Hg 
was associated with a significantly lower risk of 
death from stroke (hazard ratio, 0.36–0.67) and 
ischemic heart disease (hazard ratio, 0.49–0.67), 
whereas diastolic BP levels within the reference 
range (70–79 mm Hg) confer the lowest risk of 
major vascular events and ischemic stroke.22,23
The new scores (TAbLE 3) are now open to pro‑
spective validation in larger patient cohorts, 
which may lead to some modifications.
Of note, the prevalence of resistant hyperten‑
sion is independently associated with coronary 
artery disease, cardiovascular death, and RF im‑
pairment.24 Renovascular disease has a relevant 
deleterious effect on BP and RF control and it 
affects long ‑term cardiovascular prognosis.15,18
The role of baseline systolic BP or mean BP in 
response prediction has been addressed by oth‑
er investigators using research tools different 
from those applied in this study.25-27 In general, 
the higher the systolic BP, the greater BP improve‑
ment after renal intervention. However, the pre‑
dictive accuracy of such a simplified approach 
reaches approximately 50%.11,19,28 Adopting an‑
other approach, Modrall et al27 have recently iden‑
tified the following independent predictors of 
a positive BP response: requirement for 4 or more 
drugs (OR, 5.9; P <0.001), preprocedural diastolic 
BP >90 mm Hg (OR, 13.9; P <0.001), and prepro‑
cedural clonidine use (OR, 4.52; P = 0.008), but 
they have not translated those into a prediction 
score. Beyond the number of antihypertensive 
drugs (presumably in optimized doses), others 
have reported a role of renal parenchymal thick‑
ness, bilateral renal artery disease, brain natri‑
uretic peptide levels, renal fractional flow reserve, 
translesional pressure gradient, and renal flow 
frame count on a dynamic angiogram.29-31 Some 
authors have reported an improved BP response 
when treating lesions with resting or hyperemic 
parameter ‑based scores of the favorable BP and 
RF response to ARAS revascularization in patients 
who meet both the angiographic and duplex ul‑
trasound criteria of stenosis severity exceeding 
60% lumen reduction.
TAbLE 2 Baseline characteristics of 202 study participants with atherosclerotic 
renal artery stenosis based on clinical, renal Doppler ultrasonography, and 
angiographic data
Parameter Value
Men, n (%) 111 (54.9)
Age, y, median (IQR) 67 (60–74)
Blood pressure–lowering drugs, n, median (IQR) 3 (3–4)




Current smoking status 96 (47.5)
BMI, kg/m2, mean (SD) 27.5 (6.1)
Prior IS 22 (10.9)
Prior MI 33 (16.3)
LVEF ≤45% 17 (8.4)
Prior flash pulmonary edema 11 (5.4)
Prior hypertension crisis 95 (47)
Coexistent atherosclerotic lesions >50%
CAD 139 (68.8)
Internal carotid artery disease 77 (38.1)
Peripheral athero ‑oclussive disease 69 (34.1)
Baseline blood pressure and renal function parameters
SBP, mm Hg, median (IQR) 145 (134–164)
DBP, mm Hg, median (IQR) 80 (74–90)
Serum creatinine, µmol/l, median (IQR) 114 (94–155)
eGFR, ml/min/1.73 m2, median (IQR) 48.6 (35.7–67.6)
eGFR >30 ml/min/1.73 m2 168 (83.2)
Angiographic and procedural parameters
Degree of renal artery lumen stenosis, %, mean (SD) 74 (14)
PTA of unilateral RAS 137 (67.8)
PTA of bilateral RAS 35 (17.3)
PTA of a single functioning kidney 30 (14.9)
Stent implantation 202 (100)
Stent diameter, mm, mean (SD) 5.74 (0.95)
Stent length, mm, mean (SD) 16.3 (4.2)
Ultrasonographic parameters
Aortic systolic velocity, m/s, mean (SD) 0.86 (0.19)
Peak systolic velocity in the index renal artery, m/s, mean (SD) 3.9 (1.23)
End ‑diastolic velocity in the index renal artery, m/s, mean (SD) 1 (0.46)
Renal ‑aortic ratio for index renal artery, mean (SD) 4.73 (1.75)
Resistive index in the index renal artery, mean (SD) 0.74 (0.06)
Intrarenal resistive index in the index kidney, mean (SD) 0.64 (0.09)
Acceleration time in the index kidney, ms, mean (SD) 122 (45)
Index kidney length, mm, mean (SD) 99.4 (11.7)
Contralateral kidney length, mm, mean (SD) 102.4 (16.9)
Data are presented as number (percentage) of patients unless otherwise indicated.
Abbreviations: IS, ischemic stroke; others, see TAbLE 1
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Despite a general agreement on the role of 
baseline RF and kidney parameters in predicting 
RF response,13,15,30,32,33 the RF response to ARAS‑
‑PTA has been even more controversial than BP 
response. Kalra et al13 reported that ARAS re‑
vascularization in chronic kidney disease stages 
3–5 was independently associated with improve‑
ment in RF at 1 year. In another small study that 
included only patients with baseline serum cre‑
atinine levels above 1.5 mg/dl yet below 4 mg/dl 
and bilateral RAS or a single functioning kidney 
in the context of ARAS, RF improved or stabi‑
lized in all patients after PTA.6 Several other fac‑
tors have been indicated in association with a re‑
duced likelihood of a favorable RF response, in‑
cluding age above 65 years, male sex, severe ath‑
erosclerotic disease, proteinuria >1 g/d, severely 
impaired RF (eGFR <40 ml/min/1.73 m2), diabe‑
tes, and the RAS degree <70%.29,33,34 Our data are 
consistent with these findings, as (having recruit‑
ed patients with significant ARAS assessed by 
angiography, which required confirmation of re‑
nal artery flow impairment on ultrasonography) 
we showed that eGFR below 30 ml/min/1.73 m2 
reduced the likelihood of favorable RF response 
(TAbLE 3). Our RF response prediction model in‑
cluded preprocedural serum creatinine lev‑
el >122 µmol/l and eGFR >30 ml/min/1.73 m2 (3 
points), and it also indicated the crucial role of pa‑
rameters assessed by preprocedural renal ultraso‑
nography, including index kidney length >98 mm 
(3 points), index EDV >1.1 m/s (2 points), and 
index artery RI <0.74 (2 points). Thus, for a fa‑
vorable RF response, preprocedural RF should 
be significantly decreased, while kidney size 
pressure gradients exceeding 20 mm Hg,29,30 but 
the physiological assessment of ARAS using the 
Pd/Pa ratio (pressure ratio, across stenosis) and 
papaverine ‑induced renal fractional flow reserve 
did not predict BP response after PTA in a more 
recent study.30
Our study provided new data that recon‑
cile several prior discrepancies. Our prediction 
score of BP improvement following ARAS ‑PTA 
includes preprocedural systolic BP of at least 
145 mm Hg or higher (3 points) and diastolic 
BP of 83 mm Hg or higher (4 points) in medi‑
cally treated patients, ARAS revascularization of 
a single functioning kidney (2 points), and bilat‑
eral PTA (1 point). Patients who scored 3 points 
or less had a low probability of BP improvement 
following PTA. Importantly, those with poorly 
controlled elevated systolic BP and with ARAS 
limited to one side (in the presence of a normal 
contralateral renal artery) had low probability 
(<25%) of BP improvement following PTA. Re‑
gardless whether ARAS involved a single func‑
tioning kidney or was bilateral, ARAS ‑PTA was 
similarly ineffective in well ‑controlled BP. On 
the other end of the spectrum, patients who 
obtained 6 points or more in the BP response 
prediction score (TAbLE 3) had about 93% proba‑
bility of positive BP response following ARAS‑
‑PTA. Our study confirmed the greatest benefit 
of PTA in patients with single functioning kidney 
or bilateral ARAS coexistent with elevated sys‑
tolic and diastolic BP (9 or 8 points), or at least 
elevated above the thresholds systolic and di‑
astolic BP in patients with unilateral ARAS (7 
points) (TAbLE 3).
TAbLE 3 Multivariable logistic regression analysis and the prediction score for the probability of favorable blood 
pressure or renal function response
Variable OR (95% CI) P value Points assigned
Favors blood pressure response
Preprocedural systolic BP ≥145 mm Hg 5.42 (2.64–11.1) <0.001 +3
Preprocedural diastolic BP ≥83 mm Hg 6.63 (3.07–14.3) <0.001 +4
PTA of a single functioning kidney 3.09 (0.92–10.4) 0.07 +2
PTA of bilateral renal artery stenosis 2.56 (1.2–5.49) 0.02 +1
Probability of positive blood pressure response Score Prevalence of responders, %
Low ≤2 points 25.3
Medium 3–5 points 66.7
High ≥6 points 93.3
Favors renal function response
Preprocedural serum creatinine level >122 µmol/l 
and eGFR >30 ml/min/1.73 m2
3.71 (1.88–7.32) <0.001 +3
Index kidney length >98 mm 3.21 (1.63–6.32) 0.001 +3
End ‑diastolic velocity >1.1 m/s in the renal artery 2.72 (1.35–5.48) 0.005 +2
Preprocedural index artery resistive index <0.74 2.33 (1.19–4.56) 0.01 +2
Probability of positive renal function response Score Prevalence of responders, %
Low ≤3 points 10.9
Medium 4–7 points 33
High ≥8 points 77.3
Abbreviations: see TAbLE 1
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preserved, in the presence of either high EDV 
or preserved index renal artery RI. Of note, pre‑
procedural EDV >1.1 m/s is an indicator of se‑
vere ARAS, while RI, of renal and intrarenal ar‑
terial stiffness.32
Limitations Our findings were based on a ret‑
rospective, single ‑center study. As the approach 
to patients with ARAS referred for PTA is sub‑
ject to change over time, the proposed predic‑
tion scores should be further validated in a pro‑
spective manner, preferably in a multicenter clin‑
ical study setting.
Conclusions In conclusion, as PTA for ARAS 
should be performed in patients who are likely 
to benefit in terms of a reduced risk of cardiovas‑
cular events (cardiac ischemia, stroke, and death), 
the proposed predictive models, although they re‑
quire further validation, may advise clinicians on 
patient selection for PTA.
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